While the oncology community is large, Jazz focuses on smaller groups of people facing unique challenges and difficult odds, such as those living with small cell lung cancer (SCLC). In the U.S., approximately 13 percent of lung cancers are small cell and nearly 30,000 new cases of SCLC are recorded in the U.S. every year.1
Jazz creates a thoughtful development strategy for every molecule and treatment we pursue through our comprehensive research and development efforts. Critical to these efforts are our partnerships with leading patient advocacy organizations like LUNGevity. These partnerships allow us to gain important insights and work towards the common goal of supporting patients and their caregivers throughout their journey.
While our priority is to deliver novel therapies to cancer communities with unmet needs, we are equally dedicated to supporting people living with difficult-to-treat cancers and their loved ones, to ensure that they have access to educational, psychosocial and community support resources along their survivorship paths.
Jazz’s Anne Borgman, MD, Vice President and Head of Hematology-Oncology Clinical Development, met with Andrea Ferris, President and CEO of LUNGevity, a U.S. based lung cancer patient advocacy group, to have an informative discussion on the importance of research and development, partnerships and innovation to address the unmet needs of the SCLC community.
1American Cancer Society. Cancer Facts & Figures 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf (accessed May 22, 2020).
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.